References
- National Cancer Institute. NCI – Endometrial Cancer. 2021 [cited 2021 Feb 2]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/endometrial-cancer
- Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2001;15(3):341–354.
- Cancer.Net. Uterine Cancer: Statistics. 2020 [cited 2020 Feb 4]. Available from: https://www.cancer.net/cancer-types/uterine-cancer/statistics
- Kurra V, Krajewski KM, Jagannathan J, et al. Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging. 2013;13:113–122.
- Rauh-Hain JA, Del Carmen MG. Treatment for advanced and recurrent endometrial carcinoma: combined modalities. Oncologist. 2010;15(8):852–861.
- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Uterine Neoplasms v1.2021 © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. [cited 2021 Jan 12]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. National Comprehensive Cancer Network.
- Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2–30.
- Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. 2021;31(1):12–39.
- Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi33–8.
- Sundar S, Balega J, Crosbie E, et al. BGCS uterine cancer guidelines: recommendations for practice. 2017. https://www.bgcs.org.uk/wp-content/uploads/2019/05/BGCS-Endometrial-Guidelines-2017.pdf
- Arabi H, Guan H, Kumar S, et al. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma.Gynecol Oncol. 2009;113(2):153–158.
- Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. J Clin Oncol Precis Oncol. 2017;2017:PO.17.00073.
- Cortes-Ciriano I, Lee S, Park WY, et al. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017;8:15180.
- Cristescu RLK, Pruitt S. Prevalence of high microsatellite instability in cancer patients in the real world. Washington (DC): SITC; 2018.
- Hause RJ, Pritchard CC, Shendure J, et al. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016;22(11):1342–1350.
- Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413.
- Lorenzi MAM, Zhang J, Mehta S, et al. P585 structured literature review and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in endometrial and ovarian cancers. Washington (DC): SITC; 2018.
- Merck S, Dohme C. A clinical trial of pembrolizumab (MK-3475) evaluating predictive biomarkers in subjects with advanced solid tumors (KEYNOTE 158). P158V02MK3475. 2018.
- US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2017.
- O'Malley D, Marabelle A, De Jesus-Acosta A, et al. Pembrolizumab in patients with MSI-H advanced endometrial cancer from the keynote-158 study. ESMO 2019 Congress. Ann Oncol. 2019;30:v425–v34.
- Barrington DA, Dilley SE, Smith HJ, et al. Pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis. Gynecol Oncol. 2019;153(2):381–384.
- Institute for Clinical and Economic Review. ICER’s reference case for economic evaluations: principles and rationale. Institute for Clinical and Economic Review; 2020. http://icer-review.org/wp-content/uploads/2020/01/ICER_Reference_Case_013120.pdf.
- Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796–797.
- Beth Woods ES, Stephen P, Nick L, et al. NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care: a critical review. NICE Decision Support Unit; 2017.
- Neumann PJ, Sanders GD, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 2016.
- Merck S, Dohme C. Lenvatinib in combination with pembrolizumab versus treatment of physician's choice in participants with advanced endometrial cancer [KEYNOTE-775]. 2020.
- McMeekin S, Dizon D, Barter J, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol. 2015;138(1):18–23.
- Miller DS, Scambia G, Bondarenko I, et al. ZoptEC: phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155). J Clin Oncol. 2018;36(15):5503.
- Di Legge A, Trivellizzi IN, Moruzzi MC, et al. Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer. Int J Gynecol Cancer. 2011;21(8):1446–1451.
- Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88(3):277–281.
- Makker V, Hensley ML, Zhou Q, et al. Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel/carboplatin: Memorial Sloan-Kettering Cancer Center experience from 1995 to 2009.Int J Gynecol Cancer. 2013;23(5):929–934.
- National Center for Health Statistics. United States life tables. NVSR. 2017;68(7):66. (PHS) 2019-1120. Centers for Disease Control and Prevention.
- Agency for Healthcare Research and Quality. HCUPnet – healthcare costs and utilization project. 2019 [cited 2019 Dec 10]. Available from: https://hcupnet.ahrq.gov/#setup
- Disutility [Internet]. York; York Health Economics Consortium; 2016 [cited 2021 Feb 2]. Available from: https://yhec.co.uk/glossary/disutility/
- CMS. Centres for Medicare and Medicaid Services, Clinical Laboratory Fee Schedule. 2020 [cited 2020 May 5]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/Clinical-Laboratory-Fee-Schedule-Files
- CMS. Physician Fee Schedule – CY 2020 Physician Fee Schedule Final Rule. 2020 [cited 2020 Feb 3]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched
- IQVIA. MSI/MMR treatment. Market Research [Merck - Data on file]. 2020.
- US Food and Drug Administration. FDA. Taxol (paclitaxel) injection - Prescribing information. 2021 [cited 2021 Feb 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf
- US Food and Drug Administration. FDA. Doxorubicin hydrochloride injection - Prescribing information. 2021 [cited 2021 Feb 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/050467s073lbl.pdf
- IBM Micromedex. Red Book Search Results. 2020 [cited 2020 Feb 11]. Available from: https://www.micromedexsolutions.com/micromedex2/librarian/CS/F4EC4C/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/58F466/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/redbook.FindRedBook?navitem=topRedBook&isToolPage=true
- Du Bois D and Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–871.
- Electronic Medicines Compendium. Tamoxifen 20mg Film-Coated Tablets, Summary of Product Characteristics. 2020.
- CMS. Centres for Medicare and Medicaid Services, Hospital Outpatient Prospective Payment System. 2020 [cited 2020 May 5]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS
- Institute for Clinical and Economic Review. Poly ADP-Ribose Polymerase (PARP) Inhibitors for Ovarian Cancer: Effectiveness & Value. 2017 [cited 2020 May 5]. Available from: http://icerorg.wpengine.com/wp-content/uploads/2020/10/MWCEPAC_OVARIAN_FINAL_EVIDENCE_REPORT_10112017-1.pdf
- Bekelman JE, Halpern SD, Blankart CR, et al. Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. JAMA. 2016;315(3):272–283.
- Briggs A, Claxton, K, Sculpher, M. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
- Simeone JC, Shah S, Ganz ML, et al. Healthcare resource utilization and cost among patients with type 1 diabetes in the United States. J Manag Care Spec Pharm. 2020;26(11):1399–1410.
- Bice T, Cox CE and Carson SS. Cost and healthcare utilization in ARDS–different from other critical illness? Semin Respir Crit Care Med. 2013;34(04):529–536.
- Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220.